Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by ten Bokkel Huinink, W.
Right arrow Articles by Heron, J. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by ten Bokkel Huinink, W.
Right arrow Articles by Heron, J. F.

Journal of Clinical Oncology, Vol 15, 2183-2193, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

W ten Bokkel Huinink, M Gore, J Carmichael, A Gordon, J Malfetano, I Hudson, C Broom, C Scarabelli, N Davidson, M Spanczynski, G Bolis, H Malmstrom, R Coleman, SC Fields and JF Heron
The Netherlands Cancer Institute, Amsterdam. wtbh@nki.nl

PURPOSE: Topotecan and paclitaxel were evaluated in a randomized, multicenter study of patients with advanced epithelial ovarian carcinoma who had progressed during or after one platinum-based regimen. PATIENTS AND METHODS: Patients received either topotecan (1.5 mg/m2) as a 30-minute infusion daily for 5 days every 21 days (n = 112) or paclitaxel (175 mg/m2) infused over 3 hours every 21 days (n = 114). Patients had bidimensionally measurable disease and were assessed for efficacy and toxicity. RESULTS: Response rate was 23 of 112 (20.5%) in topotecan-treated patients and 15 of 114 (13.2%) in paclitaxel-treated patients (P = .138). Disease stabilization for at least 8 weeks was noted in 30% of patients with topotecan and 33% of patients with paclitaxel. Median durations of response to topotecan and paclitaxel were 32 and 20 weeks, respectively (P = .222) and median times to progression were 23 and 14 weeks, respectively (P = .002). Median survival was 61 weeks for topotecan and 43 weeks for paclitaxel (P = .515). Response rates for topotecan and paclitaxel were 13.3% versus 6.7% (P = .303) in resistant patients (not responded to prior platinum- based therapy or progressed within 6 months of an initial response) and 28.8% versus 20.0% (P = .213) in sensitive patients (progressed > 6 months after response). Neutropenia was significantly more frequent on the topotecan arm 79% versus paclitaxel arm 23% (P < .01). It was short- lasting and noncumulative in both arms. Nonhematologic toxicities were generally mild (grades 1 to 2) for both agents. CONCLUSION: Topotecan has efficacy at least equivalent to paclitaxel manifested by the higher response rate and significantly longer time to progression.


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
A. X. Zhu, N. Ready, J. W. Clark, H. Safran, A. Amato, N. Salem, S. Pace, X. He, N. Zvereva, T. J. Lynch, et al.
Phase I and Pharmacokinetic Study of Gimatecan Given Orally Once a Week for 3 of 4 Weeks in Patients with Advanced Solid Tumors
Clin. Cancer Res., January 1, 2009; 15(1): 374 - 381.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
H. W Tuffaha, I. M Treish, and L. Zaru
The use and effectiveness of granulocyte colony-stimulating factor in primary prophylaxis for febrile neutropenia in the outpatient setting
Journal of Oncology Pharmacy Practice, September 1, 2008; 14(3): 131 - 138.
[Abstract] [PDF]

Home page
 JCOHome page
J. Sehouli, D. Stengel, G. Oskay-Oezcelik, A. G. Zeimet, H. Sommer, P. Klare, M. Stauch, A. Paulenz, O. Camara, E. Keil, et al.
Nonplatinum Topotecan Combinations Versus Topotecan Alone for Recurrent Ovarian Cancer: Results of a Phase III Study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group
J. Clin. Oncol., July 1, 2008; 26(19): 3176 - 3182.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. O'Brien, J. Eckardt, and R. Ramlau
Recent Advances with Topotecan in the Treatment of Lung Cancer
Oncologist, October 1, 2007; 12(10): 1194 - 1204.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. G. Mutch, M. Orlando, T. Goss, M. G. Teneriello, A. N. Gordon, S. D. McMeekin, Y. Wang, D. R. Scribner Jr, M. Marciniack, R. W. Naumann, et al.
Randomized Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer
J. Clin. Oncol., July 1, 2007; 25(19): 2811 - 2818.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Markman
New, Expanded, and Modified Use of Approved Antineoplastic Agents in Ovarian Cancer
Oncologist, February 1, 2007; 12(2): 186 - 190.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. E.R. O'Brien, T.-E. Ciuleanu, H. Tsekov, Y. Shparyk, B. Cucevia, G. Juhasz, N. Thatcher, G. A. Ross, G. C. Dane, and T. Crofts
Phase III Trial Comparing Supportive Care Alone With Supportive Care With Oral Topotecan in Patients With Relapsed Small-Cell Lung Cancer
J. Clin. Oncol., December 1, 2006; 24(34): 5441 - 5447.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
J. Pfisterer, B. Weber, A. Reuss, R. Kimmig, A. du Bois, U. Wagner, H. Bourgeois, W. Meier, S. Costa, J.-U. Blohmer, et al.
Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
J Natl Cancer Inst, August 2, 2006; 98(15): 1036 - 1045.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncolHome page
R. Saito, M. T. Krauze, C. O. Noble, D. C. Drummond, D. B. Kirpotin, M. S. Berger, J. W. Park, and K. S. Bankiewicz
Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model
Neuro-oncol, July 1, 2006; 8(3): 205 - 214.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
T. Ohta, M. Ohmichi, T. Hayasaka, S. Mabuchi, M. Saitoh, J. Kawagoe, K. Takahashi, H. Igarashi, B. Du, M. Doshida, et al.
Inhibition of Phosphatidylinositol 3-Kinase Increases Efficacy of Cisplatin in in Vivo Ovarian Cancer Models
Endocrinology, April 1, 2006; 147(4): 1761 - 1769.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P. Viens, T. Petit, A. Yovine, P. Bougnoux, G. Deplanque, P.-H. Cottu, R. Delva, J.-P. Lotz, S. V. Belle, J.-M. Extra, et al.
A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients
Ann. Onc., March 1, 2006; 17(3): 429 - 436.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
D. K. Armstrong, D. Spriggs, J. Levin, R. Poulin, and S. Lane
Hematologic Safety and Tolerability of Topotecan in Recurrent Ovarian Cancer and Small Cell Lung Cancer: An Integrated Analysis
Oncologist, October 1, 2005; 10(9): 686 - 694.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Mirchandani, H. Hochster, A. Hamilton, L. Liebes, H. Yee, J. P. Curtin, S. Lee, J. Sorich, C. Dellenbaugh, and F. M. Muggia
Phase I Study of Combined Pegylated Liposomal Doxorubicin with Protracted Daily Topotecan for Ovarian Cancer
Clin. Cancer Res., August 15, 2005; 11(16): 5912 - 5919.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. G. Dark, A. H. Calvert, R. Grimshaw, C. Poole, K. Swenerton, S. Kaye, R. Coleman, G. Jayson, T. Le, S. Ellard, et al.
Randomized Trial of Two Intravenous Schedules of the Topoisomerase I Inhibitor Liposomal Lurtotecan in Women With Relapsed Epithelial Ovarian Cancer: A Trial of the National Cancer Institute of Canada Clinical Trials Group
J. Clin. Oncol., March 20, 2005; 23(9): 1859 - 1866.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
P. G. Rose
Pegylated Liposomal Doxorubicin: Optimizing the Dosing Schedule in Ovarian Cancer
Oncologist, March 1, 2005; 10(3): 205 - 214.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Sabbatini, C. Aghajanian, D. Dizon, S. Anderson, J. Dupont, J. V. Brown, W. A. Peters, A. Jacobs, A. Mehdi, S. Rivkin, et al.
Phase II Study of CT-2103 in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
J. Clin. Oncol., November 15, 2004; 22(22): 4523 - 4531.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. J. Herzog
Recurrent Ovarian Cancer: How Important Is It to Treat to Disease Progression?
Clin. Cancer Res., November 15, 2004; 10(22): 7439 - 7449.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. Apolone and A. Buda
Topotecan versus paclitaxel in second-line therapy: a lost opportunity for quality-of-life evaluation?
Ann. Onc., September 1, 2004; 15(9): 1443 - 1444.
[Full Text] [PDF]

Home page
 JCOHome page
M. Markman, J. Markman, K. Webster, K. Zanotti, B. Kulp, G. Peterson, and J. Belinson
Duration of Response to Second-Line, Platinum-Based Chemotherapy for Ovarian Cancer: Implications for Patient Management and Clinical Trial Design
J. Clin. Oncol., August 1, 2004; 22(15): 3120 - 3125.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. De Placido, G. Scambia, G. Di Vagno, E. Naglieri, A. V. Lombardi, R. Biamonte, M. Marinaccio, G. Carteni, L. Manzione, A. Febbraro, et al.
Topotecan Compared With No Therapy After Response to Surgery and Carboplatin/Paclitaxel in Patients With Ovarian Cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) Randomized Study
J. Clin. Oncol., July 1, 2004; 22(13): 2635 - 2642.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Iop, A. M. Manfredi, and S. Bonura
Fatigue in cancer patients receiving chemotherapy: an analysis of published studies
Ann. Onc., May 1, 2004; 15(5): 712 - 720.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Reinartz, S. Kohler, H. Schlebusch, K. Krista, P. Giffels, K. Renke, J. Huober, V. Mobus, R. Kreienberg, A. duBois, et al.
Vaccination of Patients with Advanced Ovarian Carcinoma with the Anti-Idiotype ACA125: Immunological Response and Survival (Phase Ib/II)
Clin. Cancer Res., March 1, 2004; 10(5): 1580 - 1587.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
D. K. Armstrong
Topotecan Dosing Guidelines in Ovarian Cancer: Reduction and Management of Hematologic Toxicity
Oncologist, February 1, 2004; 9(1): 33 - 42.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. Hochster, E. R. Plimack, C. D. Runowicz, J. Speyer, R. C. Wallach, J. Sorich, J. Mandeli, S. Wadler, J. Wright, and F. M. Muggia
Biweekly 72-Hour 9-Aminocamptothecin Infusion As Second-Line Therapy for Ovarian Carcinoma: Phase II Study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group
J. Clin. Oncol., January 1, 2004; 22(1): 120 - 126.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
W. ten Bokkel Huinink, S. R. Lane, and G. A. Ross
Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma
Ann. Onc., January 1, 2004; 15(1): 100 - 103.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Beran, S. O'Brien, D. A. Thomas, H. T. Tran, J. E. Cortes-Franco, F. Giles, E. Estey, and H. M. Kantarjian
Phase I Study of Oral Topotecan in Hematological Malignancies
Clin. Cancer Res., September 15, 2003; 9(11): 4084 - 4091.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. P. Braybrooke, E. Boven, N. P. Bates, R. Ruijter, N. Dobbs, P. D. Cheverton, H. M. Pinedo, and D. C. Talbot
Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f ), using a weekly 30-minute intravenous infusion, in patients with advanced solid malignancies
Ann. Onc., June 1, 2003; 14(6): 913 - 921.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. A. Bookman
Developmental Chemotherapy and Management of Recurrent Ovarian Cancer
J. Clin. Oncol., May 15, 2003; 21(90100): 149s - 167.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Sehouli, D. Stengel, G. Oskay, O. Camara, H.-J. Hindenburg, P. Klare, J. Blohmer, G. Heinrich, D. Elling, P. Ledwon, et al.
A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy
Ann. Onc., November 1, 2002; 13(11): 1749 - 1755.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
T. J. Herzog
Update on the Role of Topotecan in the Treatment of Recurrent Ovarian Cancer
Oncologist, October 1, 2002; 7(90005): 3 - 10.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C. J. Dunton
Management of Treatment-Related Toxicity in Advanced Ovarian Cancer
Oncologist, October 1, 2002; 7(90005): 11 - 19.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
D. K. Armstrong
Relapsed Ovarian Cancer: Challenges and Management Strategies for a Chronic Disease
Oncologist, October 1, 2002; 7(90005): 20 - 28.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. L. Coleman
Emerging Role of Topotecan in Front-Line Treatment of Carcinoma of the Ovary
Oncologist, October 1, 2002; 7(90005): 46 - 55.
[Abstract] [Full Text] [PDF]

Home page
 Reproductive SciencesHome page
A. Hasenburg, D.-C. Fischer, X.-W. Tong, A. Rojas-Martinez, R. H. Kaufman, I. Ramzy, P. Kohlberger, M. Orlowska-Volk, E. Aguilar-Cordova, and D. G. Kieback
Adenovirus-Mediated Thymidine Kinase Gene Therapy for Recurrent Ovarian Cancer: Expression of Coxsackie-Adenovirus Receptor and Integrins {alpha}v{beta}3 and {alpha}v{beta}5
Reproductive Sciences, May 1, 2002; 9(3): 174 - 180.
[Abstract] [PDF]

Home page
 JCOHome page
S. A. Cannistra
Is There a "Best" Choice of Second-Line Agent in the Treatment of Recurrent, Potentially Platinum-Sensitive Ovarian Cancer?
J. Clin. Oncol., March 1, 2002; 20(5): 1158 - 1160.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Garcia-Carbonero and J. G. Supko
Current Perspectives on the Clinical Experience, Pharmacology, and Continued Development of the Camptothecins
Clin. Cancer Res., March 1, 2002; 8(3): 641 - 661.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
V. Dieras, P. Bougnoux, T. Petit, P. Chollet, P. Beuzeboc, C. Borel, F. Husseini, A. Goupil, P. Kerbrat, J. L. Misset, et al.
Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin {+/-} taxane-pretreated ovarian cancer patients
Ann. Onc., February 20, 2002; 13(2): 258 - 266.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Montazeri, S. Culine, B. Laguerre, F. Pinguet, F. Lokiec, N. Albin, A. Goupil, R. Deporte-Fety, R. Bugat, P. Canal, et al.
Individual Adaptive Dosing of Topotecan in Ovarian Cancer
Clin. Cancer Res., February 1, 2002; 8(2): 394 - 399.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Guichard, A. Montazeri, E. Chatelut, I. Hennebelle, R. Bugat, and P. Canal
Schedule-dependent Activity of Topotecan in OVCAR-3 Ovarian Carcinoma Xenograft: Pharmacokinetic and Pharmacodynamic Evaluation
Clin. Cancer Res., October 1, 2001; 7(10): 3222 - 3228.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. N. Gordon, J. T. Fleagle, D. Guthrie, D. E. Parkin, M. E. Gore, and A. J. Lacave
Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan
J. Clin. Oncol., July 15, 2001; 19(14): 3312 - 3322.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Bowman, T. Rye, G. Ross, A. Wheatley, and J. F. Smyth
Effective Dosing of Topotecan With Carboplatin in Relapsed Ovarian Cancer: A Phase I/II Study
J. Clin. Oncol., July 1, 2001; 19(13): 3255 - 3259.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Gore, W. ten Bokkel Huinink, J. Carmichael, A. Gordon, N. Davidson, R. Coleman, M. Spaczynski, J.-F. Heron, G. Bolis, H. Malmstrom, et al.
Clinical Evidence for Topotecan-Paclitaxel Non-Cross-Resistance in Ovarian Cancer
J. Clin. Oncol., April 1, 2001; 19(7): 1893 - 1900.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Maliepaard, M. A. van Gastelen, A. Tohgo, F. H. Hausheer, R. C. A. M. van Waardenburg, L. A. de Jong, D. Pluim, J. H. Beijnen, and J. H. M. Schellens
Circumvention of Breast Cancer Resistance Protein (BCRP)-mediated Resistance to Camptothecins in Vitro Using Non-Substrate Drugs or the BCRP Inhibitor GF120918
Clin. Cancer Res., April 1, 2001; 7(4): 935 - 941.
[Abstract] [Full Text]

Home page
 JCOHome page
C. Doyle, M. Crump, M. Pintilie, and A. M. Oza
Does Palliative Chemotherapy Palliate? Evaluation of Expectations, Outcomes, and Costs in Women Receiving Chemotherapy for Advanced Ovarian Cancer
J. Clin. Oncol., March 1, 2001; 19(5): 1266 - 1274.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. E. Royce, P. M. Hoff, P. Dumas, Y. Lassere, J. J. Lee, J. Coyle, M. P. Ducharme, R. De Jager, and R. Pazdur
Phase I and Pharmacokinetic Study of Exatecan Mesylate (DX-8951f): A Novel Camptothecin Analog
J. Clin. Oncol., March 1, 2001; 19(5): 1493 - 1500.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. J. Schilder, J. M. Gallo, M. M. Millenson, M. A. Bookman, L. M. Weiner, A. Rogatko, B. Rogers, K. Padavic-Shallers, M. Boente, N. Rosenblum, et al.
Phase I Trial of Multiple Cycles of High-Dose Carboplatin, Paclitaxel, and Topotecan With Peripheral-Blood Stem-Cell Support as Front-Line Therapy
J. Clin. Oncol., February 15, 2001; 19(4): 1183 - 1194.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
I. A. Malik
Altretamine is an Effective Palliative Therapy of Patients with Recurrent Epithelial Ovarian Cancer
Jpn. J. Clin. Oncol., February 1, 2001; 31(2): 69 - 73.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Hoskins, E. Eisenhauer, I. Vergote, J. Dubuc-Lissoir, B. Fisher, R. Grimshaw, A. Oza, M. Plante, G. Stuart, and J. Vermorken
Phase II Feasibility Study of Sequential Couplets of Cisplatin/Topotecan Followed by Paclitaxel/Cisplatin as Primary Treatment for Advanced Epithelial Ovarian Cancer: A National Cancer Institute of Canada Clinical Trials Group Study
J. Clin. Oncol., December 15, 2000; 18(24): 4038 - 4044.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
P. J. Stiff, J. Veum-Stone, H. M. Lazarus, L. Ayash, J. R. Edwards, A. Keating, J. P. Klein, D. J. Oblon, T. C. Shea, S. Thome, et al.
High-Dose Chemotherapy and Autologous Stem-Cell Transplantation for Ovarian Cancer: An Autologous Blood and Marrow Transplant Registry Report
Ann Intern Med, October 3, 2000; 133(7): 504 - 515.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. F. Verschraegen, T. Sittisomwong, A. P. Kudelka, E. d. P. Guedes, M. Steger, T. Nelson-Taylor, M. Vincent, R. Rogers, E. N. Atkinson, and J. J. Kavanagh
Docetaxel for Patients With Paclitaxel-Resistant Mullerian Carcinoma
J. Clin. Oncol., July 14, 2000; 18(14): 2733 - 2739.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. J. A. de Jonge, W. J. Loos, H. Gelderblom, A. S. Th. Planting, M. E. L. van der Burg, A. Sparreboom, E. Brouwer, V. van Beurden, M. A. Mantel, E. Doyle, et al.
Phase I Pharmacologic Study of Oral Topotecan and Intravenous Cisplatin: Sequence-Dependent Hematologic Side Effects
J. Clin. Oncol., May 10, 2000; 18(10): 2104 - 2115.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. J. S. Rustin, A. E. Nelstrop, S. M. Bentzen, S. J. Bond, and P. McClean
Selection of Active Drugs for Ovarian Cancer Based on CA-125 and Standard Response Rates in Phase II Trials
J. Clin. Oncol., April 1, 2000; 18(8): 1733 - 1739.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. J. Piccart, J. A. Green, A. J. Lacave, N. Reed, I. Vergote, P. Benedetti-Panici, A. Bonetti, V. Kristeller-Tome, C. M. Fernandez, D. Curran, et al.
Oxaliplatin or Paclitaxel in Patients With Platinum-Pretreated Advanced Ovarian Cancer: A Randomized Phase II Study of the European Organization for Research and Treatment of Cancer Gynecology Group
J. Clin. Oncol., March 13, 2000; 18(6): 1193 - 1202.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. P. McGuire, J. A. Blessing, M. A. Bookman, S. S. Lentz, and C. J. Dunton
Topotecan Has Substantial Antitumor Activity as First-Line Salvage Therapy in Platinum-Sensitive Epithelial Ovarian Carcinoma: A Gynecologic Oncology Group Study
J. Clin. Oncol., March 1, 2000; 18(5): 1062 - 1062.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Markman and M. A. Bookman
Second-Line Treatment of Ovarian Cancer
Oncologist, February 1, 2000; 5(1): 26 - 35.
[Abstract] [Full Text]

Home page
 JNCI J Natl Cancer InstHome page
J. E. Groopman and L. M. Itri
Chemotherapy-Induced Anemia in Adults: Incidence and Treatment
J Natl Cancer Inst, October 6, 1999; 91(19): 1616 - 1634.